Clinical Trials Logo

Refractory Tumor clinical trials

View clinical trials related to Refractory Tumor.

Filter by:

NCT ID: NCT03415477 Completed - Recurrent Disease Clinical Trials

Denosumab: A Potential Treatment Option for Aneurysmal Bone Cysts

Deno-ABC
Start date: January 1, 2014
Phase: Phase 1/Phase 2
Study type: Interventional

The efficacy of traditional therapeutic approaches for aneurysmal bone cysts (ABC), such as surgery, embolization, sclerotherapy and radiotherapy, are often compromised for lesions in axial skeletons and adolescents complicated with pathological fracture. Therefore, denosumab, a new drug that has been successfully used in giant cell tumor of bone but has seldom used in ABC, was used to treat ABC in this trial.

NCT ID: NCT03239015 Recruiting - Refractory Tumor Clinical Trials

Efficacy and Safety of Precision Therapy in Refractory Tumor

Start date: January 1, 2017
Phase: Phase 2
Study type: Interventional

This study is intended to evaluate efficacy and safety of targeted precision therapy in patients with refractory tumor, including rare tumor without standard recommended treatment and common tumor after multiple line of therapy.

NCT ID: NCT03158324 Recruiting - Refractory Tumor Clinical Trials

Phase IIa Dose-Expansion and Biomarker Study of OPB-111077

Start date: May 22, 2017
Phase: Phase 2
Study type: Interventional

This is a phase IIa open-label, non-randomized dose-expansion study of OPB-111077 in patients with advanced, treatment refractory cancers who have biopsy-amenable lesions at study entry.

NCT ID: NCT02564198 Completed - Clinical trials for Pediatric Solid Tumor

A Study of Ramucirumab (LY3009806) in Children With Refractory Solid Tumors

Start date: December 11, 2015
Phase: Phase 1
Study type: Interventional

The main purpose of this study is to evaluate the safety of the study drug known as ramucirumab in children with recurrent or refractory solid tumors including central nervous system (CNS) tumors.